[go: up one dir, main page]

PE20131377A1 - Triazina-oxadiazoles - Google Patents

Triazina-oxadiazoles

Info

Publication number
PE20131377A1
PE20131377A1 PE2013000506A PE2013000506A PE20131377A1 PE 20131377 A1 PE20131377 A1 PE 20131377A1 PE 2013000506 A PE2013000506 A PE 2013000506A PE 2013000506 A PE2013000506 A PE 2013000506A PE 20131377 A1 PE20131377 A1 PE 20131377A1
Authority
PE
Peru
Prior art keywords
alkyl
triazine
methyl
oxadiazoles
compounds
Prior art date
Application number
PE2013000506A
Other languages
English (en)
Inventor
Oliver Barker
Jonathan Mark Bentley
Thomas Cain
Praful Chovatia
Jennifer Ruth Dod
Florence Eustache
Laura Gleave
Jonathan Hargrave
Alexander Heifetz
Richard Law
Ali Raoof
David Willows
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44651777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131377(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20131377A1 publication Critical patent/PE20131377A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TRIAZINA-OXADIAZOLES DE FORMULA (I) DONDE R1 ES H, HALOGENO, ALQUILO(C1-C7), ENTRE OTROS; R2 ES H, ALQUILO(C1-C7), HALOALQUILO(C2-C7), ENTRE OTROS; R ES HALOGENO, ALCOXILO(C1-C7), CN, NITRO, ENTRE OTROS; R3 ES -C(O)-NR5'R5, -C(O)-O-R5, ENTRE OTROS, EN DONDE R5 Y R5' SON CADA UNO H, ALQUILO(C1-C7), CICLOALQUILO(C3-C10), ALCOXILO(C1-C7), ENTRE OTROS; R8 ES H; R9 ES H, ALCOXI(C1-C7)-ALQUILO(C1-C7), ALQUILO(C1-C7), ENTRE OTROS; m ES 0 O 1; n ES DE 0 A 2. SON COMPUESTOS PREFERIDOS: 2-N-METIL-2-N-FENIL-6-(5-{4-[(2,2,2-TRIFLUOROETOXI)METIL]PIPERIDIN-1-IL}-1,2,4-OXADIAZOL-3-IL)-1,3,5-TRIAZINA-2,4-DIAMINA; 2-N-METIL-2-N-FENIL-6-{5-[1-(PROPANO-2-SULFONIL)PIPERIDIN-4-IL]-1,2,4-OXADIAZOL-3-IL}-1,3,5-TRIAZINA-2,4-DIAMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL CANAL DE SODIO REGULADO POR VOLTAJE 1.7 (Nav1.7) SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR CRONICO
PE2013000506A 2010-09-13 2011-09-13 Triazina-oxadiazoles PE20131377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38215810P 2010-09-13 2010-09-13

Publications (1)

Publication Number Publication Date
PE20131377A1 true PE20131377A1 (es) 2013-11-30

Family

ID=44651777

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000506A PE20131377A1 (es) 2010-09-13 2011-09-13 Triazina-oxadiazoles

Country Status (27)

Country Link
US (2) US8895733B2 (es)
EP (1) EP2616465B1 (es)
JP (1) JP2013537180A (es)
KR (1) KR101843600B1 (es)
CN (1) CN103221408A (es)
AU (1) AU2011303978B2 (es)
BR (1) BR112013005889A2 (es)
CA (1) CA2812081A1 (es)
CL (1) CL2013000685A1 (es)
CO (1) CO6690768A2 (es)
CR (1) CR20130111A (es)
CU (1) CU20130036A7 (es)
DK (1) DK2616465T3 (es)
EA (1) EA026132B1 (es)
ES (1) ES2559449T3 (es)
HR (1) HRP20160094T1 (es)
HU (1) HUE027256T2 (es)
MX (1) MX2013002864A (es)
NZ (1) NZ608116A (es)
PE (1) PE20131377A1 (es)
PH (1) PH12013500473A1 (es)
PL (1) PL2616465T3 (es)
PT (1) PT2616465E (es)
RS (1) RS54544B1 (es)
SG (1) SG188438A1 (es)
SI (1) SI2616465T1 (es)
WO (1) WO2012035023A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188438A1 (en) * 2010-09-13 2013-05-31 Novartis Ag Triazine-oxadiazoles
BR112014010271A2 (pt) 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
TW201400446A (zh) 2012-05-22 2014-01-01 Genentech Inc Ｎ－取代之苯甲醯胺及其使用方法
CA2878478A1 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
MX385385B (es) 2012-11-21 2025-03-18 Ptc Therapeutics Inc Inhibidores de bmi-1 de pirimidina inversa sustituida.
CN105263490B (zh) 2013-03-14 2018-05-22 基因泰克公司 取代的三唑并吡啶及其使用方法
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
AU2013399092A1 (en) 2013-08-30 2016-03-17 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors
WO2015076801A1 (en) * 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted triazine bmi-1 inhibitors
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
KR20180067561A (ko) 2015-09-28 2018-06-20 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
CR20190236A (es) 2016-10-17 2019-09-09 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
IL304017A (en) 2017-01-06 2023-08-01 Yumanity Therapeutics Inc Methods for treating neurological disorders
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
CN112020500A (zh) 2017-12-22 2020-12-01 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的氨基吡啶衍生物
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
SG11202009280RA (en) 2018-03-23 2020-10-29 Yumanity Therapeutics Inc Compounds and uses thereof
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
SG11202108079RA (en) 2019-01-24 2021-08-30 Yumanity Therapeutics Inc Compounds and uses thereof
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
EP4118081A1 (en) * 2020-03-27 2023-01-18 Landos Biopharma, Inc. Plxdc2 ligands

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
EP1187825A1 (en) 1999-06-07 2002-03-20 Shire Biochem Inc. Thiophene integrin inhibitors
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
ES2575522T3 (es) 2002-07-18 2016-06-29 Janssen Pharmaceutica Nv Inhibidores de quinasas con triazina sustituida
AR045010A1 (es) * 2003-07-02 2005-10-12 Vertex Pharma Pirimidinas utiles como moduladores de canales ionicos cuya activacion es controlada por tension
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
US20080227799A1 (en) 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
AU2008256937A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
CN101784269A (zh) 2007-06-26 2010-07-21 莱西肯医药有限公司 治疗由5-羟色胺介导的疾病和病症的方法
WO2009010784A1 (en) * 2007-07-13 2009-01-22 Astrazeneca Ab New compounds 955
WO2009091388A2 (en) 2007-12-21 2009-07-23 Progenics Pharmaceuticals, Inc. Triazines and related compounds having antiviral activity, compositions and methods thereof
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8236880B2 (en) 2008-04-23 2012-08-07 Taylor Made Golf Company, Inc. Compositions comprising an amino triazine and ionomer or ionomer precursor
WO2010017368A2 (en) 2008-08-06 2010-02-11 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
WO2010022055A2 (en) * 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
CA2789711C (en) * 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
SG188438A1 (en) * 2010-09-13 2013-05-31 Novartis Ag Triazine-oxadiazoles

Also Published As

Publication number Publication date
PL2616465T3 (pl) 2016-04-29
HRP20160094T1 (hr) 2016-02-26
JP2013537180A (ja) 2013-09-30
KR20130105657A (ko) 2013-09-25
CL2013000685A1 (es) 2013-10-04
SG188438A1 (en) 2013-05-31
CO6690768A2 (es) 2013-06-17
PT2616465E (pt) 2016-03-09
EA026132B1 (ru) 2017-03-31
US20150025057A1 (en) 2015-01-22
EA201390381A1 (ru) 2013-08-30
CR20130111A (es) 2013-05-29
DK2616465T3 (da) 2016-02-01
NZ608116A (en) 2014-05-30
AU2011303978A1 (en) 2013-03-21
CN103221408A (zh) 2013-07-24
AU2011303978B2 (en) 2014-07-03
CA2812081A1 (en) 2012-03-22
PH12013500473A1 (en) 2013-05-06
EP2616465A1 (en) 2013-07-24
RS54544B1 (sr) 2016-06-30
BR112013005889A2 (pt) 2020-08-25
KR101843600B1 (ko) 2018-03-29
CU20130036A7 (es) 2013-05-31
US8895733B2 (en) 2014-11-25
US20140051676A1 (en) 2014-02-20
EP2616465B1 (en) 2015-11-04
SI2616465T1 (sl) 2016-02-29
HUE027256T2 (en) 2016-08-29
MX2013002864A (es) 2013-08-29
WO2012035023A1 (en) 2012-03-22
ES2559449T3 (es) 2016-02-12

Similar Documents

Publication Publication Date Title
PE20131377A1 (es) Triazina-oxadiazoles
PE20120008A1 (es) Derivados de fenoxi bencenosulfonamida
PE20141681A1 (es) Inhibidores de btk
PE20080927A1 (es) Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk)
PE20191757A1 (es) Compuestos heterociclicos utiles como inhibidores dobles de atx/ca
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
PE20161400A1 (es) Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer
PE20141827A1 (es) Inhibidores de proteinas quinasas
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20090592A1 (es) Nuevos derivados de piperazina-amida
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
PE20130157A1 (es) Inhibidores de la polimerasa virica
PE20081783A1 (es) Nuevas 2-aminooxazolinas como ligandos de taar1
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
AR045389A1 (es) Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA

Legal Events

Date Code Title Description
FD Application declared void or lapsed